2025-01-11
On January 10th, 2025, BOCG's portfolio company, Ribo Life Science, with its subsidiary, Ribocure Pharmaceuticals AB, announced that they have achieved a key pre-clinical milestone in their siRNA programs, less than a year into their collaboration with Boehringer Ingelheim with an overall deal value that exceeds USD 2 billion.
The following news is from Ribo Life Science:
Suzhou Ribo Life Science and Ribocure AB are excited to share that we have achieved a key pre-clinical milestone in our siRNA programs, less than a year into our collaboration with Boehringer Ingelheim.
These achievements highlight the strength of Boehringer Ingelheim's expertise in MASH and validates the power of the Ribo platform and organization. (click to view original news)
We are looking forward to advancing these and remaining ourcollaboration programs into 2025 and beyond to address high unmet patient needs.
The orginal news from Boehringer Ingelheim：
Boehringer reported progress in other partnership pipeline projects:
Together with Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), Boehringer reached a first pre-clinical milestone in the development of siRNA based treatments for metabolic dysfunction-associated steatohepatitis (MASH), less than a year after initiation of the partnership.
Link：https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/boehringer-new-partnership-and-pipeline-progress
